Ultralife Q2 Adj $0.22 Beats $0.14 Estimate, Sales $42.98M Beat $42.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ultralife (NASDAQ:ULBI) reported strong Q2 earnings, with adjusted EPS of $0.22 beating the $0.14 estimate and sales of $42.98M surpassing the $42.00M estimate. This marks a significant improvement from the previous year's losses and a notable increase in sales.
July 25, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultralife (NASDAQ:ULBI) reported Q2 adjusted EPS of $0.22, beating the $0.14 estimate by 57.14%. Sales reached $42.98M, surpassing the $42.00M estimate. This represents a significant turnaround from last year's losses and a 34.68% increase in sales.
Ultralife's strong Q2 earnings and sales performance, significantly beating analyst estimates, indicate positive momentum for the company. The substantial improvement from last year's losses and the notable increase in sales are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100